Safety Study of a Topical Treatment for Dry Age Related Macular Degeneration

Nonexudative Age-related Macular Degeneration Clinical Trial

Official title: A Phase 1 Randomized, Double-masked, Vehicle-controlled, Dose Escalation Study of the Ocular Safety and Tolerability of MC-1101 in Medically Stable Individuals

Status Completed

Clinical Trial Summary

Study to evaluate the safety and tolerability of MC-1101, a potential topical treatment for non-edxudative age Related Macular Degeneration (AMD) in medically stable individuals.

Clinical Trial Description

MC-1101 is a topical version of a previously approved anti-hypertensive drug that is intended to increase choroidal blood flow.

• A reduction of choroidal blood flow has been identified in patients with AMD

• This study will evaluate 0.5% and 1.0% potencies of MC-1101 delivered 2X per day. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Geographic Atrophy
• Macular Degeneration
• Nonexudative Age-related Macular Degeneration

• NCT number: NCT01922128
• Study type: Interventional
• Source: MacuCLEAR, Inc.
• Status: Completed
• Phase: Phase 1
• Start date: September 2013
• Completion date: December 2013